Dapoxétine HCL CAS:129938-20-1

Premature ejaculation (PE) is the most common male sexual dysfunction. hydrochloride, belonging to a class of drugs known as selective serotonin reuptake inhibitors or, was the first drug originally approved for the on-demand treatment of men with PE. We aimed to compare the intravaginal ejaculatory latency time (IELT), patient-reported global impression of change (PGIC), and adverse effect (AE) incidence associated with the use of (30 mg and 60 mg) versus placebo, and evaluate the differences in administering 60 mg versus 30 mg as on-demand medical oral therapy for the treatment of PE via a literature review and meta-analysis. Relevant randomized controlled trials (RCTs) were identified from PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (Cochrane Library) databases. Ultimately, a total of seven RCTs with 8039 patients were included. Our meta-analysis demonstrated that (in the 30 mg and 60 mg subgroup) resulted in significantly higher IELT, PGIC, and AE incidence relative to the placebo, with higher proportions observed for 60 mg versus 30 mg of administration. The most common AEs were mild and tolerable. We conclude that (particularly the 60 mg dosage) may be considered a safe and effective drug for patients with PE.

Dapoxetine hydrochloride is a drug that is used to treat premature ejaculation in men. It is available by prescription and is taken orally, prior to sexual intercourse. The drug belongs to the class called serotonin reuptake inhibitors (SSRIs), which have mainly been used to treat depression.

Sexual dysfunction, including premature ejaculation, is an extremely common condition worldwide. The cause of premature ejaculation has not been fully elucidated, but may include both psychological and physiological factors. Premature ejaculation refers to a short ejaculation time, which can affect the satisfaction of both partners during sexual intercourse.